ATR and medulloblastoma: In some cases, concomitant inhibition of both CHK1 and ATR improves therapeutic efficacy as in high-risk medulloblastomas, where high MYC levels were associated with hypersensitivity to pharmacological inhibition of either CHK1 or ATR.